Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Other Non-Current Assets (2022 - 2024)

Historic Other Non-Current Assets for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q2 2024 value amounting to $8000.0.

  • NewAmsterdam Pharma's Other Non-Current Assets fell 9210.03% to $8000.0 in Q2 2024 from the same period last year, while for Jun 2024 it was $8000.0, marking a year-over-year decrease of 9210.03%. This contributed to the annual value of $35000.0 for FY2023, which is 7756.41% down from last year.
  • NewAmsterdam Pharma's Other Non-Current Assets amounted to $8000.0 in Q2 2024, which was down 9210.03% from $16000.0 recorded in Q1 2024.
  • Over the past 5 years, NewAmsterdam Pharma's Other Non-Current Assets peaked at $101270.0 during Q2 2023, and registered a low of $148.96 during Q4 2022.
  • Its 3-year average for Other Non-Current Assets is $32083.8, with a median of $16000.0 in 2024.
  • Per our database at Business Quant, NewAmsterdam Pharma's Other Non-Current Assets skyrocketed by 2339685.47% in 2023 and then plummeted by 9210.03% in 2024.
  • Over the past 3 years, NewAmsterdam Pharma's Other Non-Current Assets (Quarter) stood at $148.96 in 2022, then soared by 23396.85% to $35000.0 in 2023, then plummeted by 77.14% to $8000.0 in 2024.
  • Its Other Non-Current Assets was $8000.0 in Q2 2024, compared to $16000.0 in Q1 2024 and $35000.0 in Q4 2023.